ClinicalTrials.gg
RecruitingNCT07311135Updated Feb 17, 2026

Accuracy of Smartwatches in Measuring Oxygen Levels in Patients With Pulmonary Hypertension: A Pilot Study

An observational study in Pulmonary Hypertension, sponsored by Golden Jubilee National Hospital. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Golden Jubilee National Hospital · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
20
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 117 studies in Hypertension, Pulmonary with a site in United Kingdom — 22 open to participants now, 27 under way, 3 of them phase 3. Hypertension, Pulmonary · United Kingdom.

Planned enrollment
29th of 33
20 · median 200
Started
2025
with 6 others
Observational
33 of 117
12 open now
Primary completion
2026-12
later than 9 of 26 live
Registered
113th of 117
by date
Lead sponsor
7 of 117
Golden Jubilee National Hospital

Among the 117 studies in Hypertension, Pulmonary with a site in United Kingdom, this one is the 29th largest by planned enrollment of the 33 observational ones that give a count, is one of 7 that started in 2025, is one of 33 observational ones, reaches primary completion later than 9 of the 26 other live ones, and was the 113th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

22 of the 117 studies in Hypertension, Pulmonary with a site in United Kingdom are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 117 studies in Hypertension, Pulmonary with a site in United Kingdom, or all of them as a file.
02

Study summary

The goal of this study is to learn how accurate smartwatches are at measuring oxygen levels in patients with a condition called pulmonary hypertension. The main questions it aims to answer are:

  • How accurate the smartwatches are at measuring oxygen levels when the patient is sitting at rest
  • How accurate are smartwatches at measuring oxygen levels after exercise
  • How accurate are smartwatches at measuring oxygen levels after breathing a lower level of oxygen through a mask.

Researchers will compare oxygen levels measured through a smartwatch with those checked through a finger probe oxygen monitor and also from a blood sample checked from the artery in the wrist to see if smartwatch oxygen measurements are similar.

Participants will:

-Attend the hospital once, just for a few hours to collect all the required data.

Read the detailed description

The goal of this pilot study is assess the accuracy of SpO2 measurements in smartwatches when compared to arterial oxygen levels and pulse oximeter readings at rest, following exercise and at simulated high altitude with the use of a hypoxic challenge test.

Patient recruitment:

Patients will be recruited prospectively from the Scottish Pulmonary Vascular Unit at the Golden Jubilee National Hospital, Glasgow, Scotland.

Patients attending outpatient clinic will be screened for eligibility. Additionally, a study poster will be displayed in the clinic waiting area. If eligible, patients will be asked if they would like to learn about the study. After discussing the study overview in person, the patient will be offered the patient information sheet to take away with them and advised that if they are interested in taking part or have any further questions about the study, they can either reply using the opt in form provided or by phoning the study team. Those patients who opt in to the trial will be contacted to provide them with a date to attend for a study visit.

On the day of the study visit, prior to commencing any study activities, participants will see a different doctor from the research team who will clarify their full understanding of the study and will give them the opportunity to complete the written study consent form.

Procedure:

During a study visit, participants will have an arterial line inserted into their radial artery by an experienced intensive care unit doctor to allow easy access to arterial blood sampling. Each paired sample will include: smartwatch oxygen saturations, arterial oxygen saturations, finger probe pulse oximeter measurements taken at the same time. Paired samples will be taken at baseline (while the patient is in a seated, rested state), post-exercise in the recovery period after a six-minute walk test and in simulated high altitude during a hypoxic challenge.

The six minute walk test will comprise shuttles of 25 metres continuously for 6 minutes. 10 paired samples will be taken during the recovery period after a six-minute walk test. The hypoxic challenge will be undertaken by asking the patient to breathe through a 40% Venturi mask driven by 100% nitrogen at a flow rate of 10L/min which will deliver an inhaled oxygen level of 15%. If SpO2 falls below 85% for over 30 seconds the test will be stopped and if required, inhaled oxygen will be delivered to correct hypoxia. The participant will breathe the air/nitrogen mixture for 20 minutes unless the procedure is aborted due to hypoxia prior to that. 10 paired samples will be taken during the hypoxic challenge test. Following completion the arterial line will be removed and pressure will be applied until any bleeding stops. Participants will be monitored for 30 minutes prior to them leaving.

Data collection/management:

Each study participant will be assigned a study number which will be used on all study documentation to avoid using patient identifiable information. All data will be stored on an NHS password encrypted computer. Data will be collected on pseudonymised data capture sheets with a study ID number and all research measurements will be transferred to an Excel spreadsheet for analysis.

Sample size:

The study is a cross sectional study of validity requiring one study visit per participant. Regarding sample size, this is a pilot study to gain initial estimates of the mean bias and limits of agreement of smartwatch measurements compared to the gold standard arterial oxygen levels. The planned sample size of 20 is not based on a sample size calculation, and is considered sufficient to obtain initial estimates, and to allow planning of larger studies if required. The investigators will aim to recruit 20 patients and will recruit up to a maximum of 25 in total if required in the case of incomplete data sets.

Statistical analysis:

The bias of smartwatches and standard pulse oximeter oxygen saturation measurements relative to the gold standard, arterial blood gas, will be compared using Bland-Altman analysis.

Plan for missing data:

In the event that an arterial sample cannot be analysed, the smartwatch and fingerprobe pulse oximeter samples will still be noted and compared. The investigators will aim to obtain 10 complete paired samples per patient after exercise and also 10 full sets during the hypoxic challenge. The investigators will aim to recruit 20 patients but will recruit up to 25 patients as required to achieve complete data sets. In the event that a smartwatch reading is not obtained during a paired sample, this will be documented as 'no measurement obtained'. This will still represent a complete paired sample as inability to obtain a measurement is useful to note as an outcome. In the event that the fingerprobe pulse oximeter is unable to obtain a reading the data will be documented as 'no measurement obtained' but will not require any increased requirement for recruitment as long as smartwatch and arterial gas measurements have been acquired as a paired sample.

03

Conditions studied

  • Pulmonary Hypertension

Keywords

  • smartwatch
  • pulmonary hypertension
  • oxygen saturations
  • SpO2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients attending outpatient clinic at the Golden Jubilee National Hospital under the care of the Scottish Pulmonary Vascular Unit.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-years old and above.
  • Diagnosed with pulmonary hypertension by right heart catheterisation showing a baseline mean pulmonary artery pressure > 20mmHg, PVR >2 Woods Units.
  • Able to perform a six-minute walk test (6MWT)
  • Able to give written .

Exclusion criteria

Exclusion Criteria:

  • Peripheral arterial disease
  • Tattoos or skin markings which cover the dorsal wrist.
  • Resting SpO2 \<88%
  • Severe concurrent medical condition that would prevent participation in study procedures or with \<3 months
  • Patients with bleeding disorders
  • Patients on anticoagulation

    • Except in circumstances where anticoagulation is given solely for historical perceived long term survival benefit for pulmonary arterial hypertension. This patient group could be given the option to come off their anticoagulation for 1 week prior to the study visit if they wished to take part in the study. It could then be restarted the day following the study visit providing there were no bleeding complications related to the arterial line.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adult patients with pulmonary hypertension

    Pre-capillary pulmonary hypertension, able to complete a six-minute walk test

06

What researchers measure

Primary outcomes

  1. Agreement of oxygen saturations (SpO2) measured by the wrist-worn pulse oximeter when compared with arterial blood gas oxygen saturations (SaO2) at rest

    SpO2 (measured by the wrist-worn pulse oximeter (smartwatch) and standard fingerprobe pulse oximeter) and SaO2 (measured by the arterial blood gas analysis) measured as a percentage.

    Time frame: 1 study visit, anticipated to be around 3 hours.

Secondary outcomes

  1. 1. Agreement of oxygen saturations (SpO2) measured by the wrist-worn pulse oximeter when compared with arterial blood gas oxygen saturations (SaO2) after exercise

    SpO2 (measured by the wrist-worn pulse oximeter (smartwatch) and standard fingerprobe pulse oximeter) and SaO2 (measured by arterial blood gas analysis) measured as a percentage after exercise

    Time frame: 1 study visit, estimated 3 hours duration

  2. 1. Agreement of oxygen saturations (SpO2) measured by the wrist-worn pulse oximeter when compared with arterial blood gas oxygen saturations (SaO2) after a hypoxic challenge

    SpO2 (measured by the wrist-worn pulse oximeter (smartwatch) and standard fingerprobe pulse oximeter) and SaO2 (measured by arterial blood gas analysis) measured as a percentage, after a hypoxic challenge test.

    Time frame: 1 study visit, estimated 3 hours duration

07

Study locations

1 of 1 sites recruiting
  • Golden Jubilee National Hospital
    Glasgow, G81 4DY, United Kingdom
    Recruiting
    • Martin Johnson, BA, MBChB(Hons), MD, FRCP · Contactmartin.johnson@nhs.scot · (0044) 0141 951 5497
    • Jamie Ingram, MBChB, BMSc, PGCert · Contactjamie.ingram2@nhs.scot · (0044) 0141 951 5497
    • Martin Johnson, BA, MBChB (Hons), MD, FRCP · Principal investigator
    • Jamie Ingram, MBChB, BMSc, PGCert · Sub investigator
    • Colin Church, BSc, MBChB, FRCP, PhD · Sub investigator
08

References and documents

Publications

  • Spaccarotella C, Polimeni A, Mancuso C, Pelaia G, Esposito G, Indolfi C. Assessment of Non-Invasive Measurements of Oxygen Saturation and Heart Rate with an Apple Smartwatch: Comparison with a Standard Pulse Oximeter. J Clin Med. 2022 Mar 8;11(6):1467. doi: 10.3390/jcm11061467. PubMed 35329793 ↗
  • Pipek LZ, Nascimento RFV, Acencio MMP, Teixeira LR. Comparison of SpO2 and heart rate values on Apple Watch and conventional commercial oximeters devices in patients with lung disease. Sci Rep. 2021 Sep 23;11(1):18901. doi: 10.1038/s41598-021-98453-3. PubMed 34556765 ↗
  • Arslan B, Sener K, Guven R, Kapci M, Korkut S, Sutasir MN, Tekindal MA. Accuracy of the Apple Watch in measuring oxygen saturation: comparison with pulse oximetry and ABG. Ir J Med Sci. 2024 Feb;193(1):477-483. doi: 10.1007/s11845-023-03456-w. Epub 2023 Jul 13. PubMed 37440093 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Dec 30, 2025
StartActual
Dec 17, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07311135
Lead sponsor
Golden Jubilee National Hospital
Responsible party
Sponsor
First posted
Dec 30, 2025
Start date
Dec 17, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Feb 17, 2026

Study contacts

Martin Johnson, BA, MBChB(Hons), MD, FRCP
Contact
martin.johnson@nhs.scot
(0044) 0141 951 5497
Jamie Ingram, MBChB, BMSc, PGCert
Contact
jamie.ingram2@nhs.scot
(0044) 0141 951 5497
Martin Johnson, BA, MBChB(Hons), MD, FRCP
principal investigator · Golden Jubilee National Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion